Health Care [ 12/12 ] | Biotechnology [ 64/74 ]
NASDAQ | Common Stock
Grifols,S. A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug.
Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development.
Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG.
It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies.
The company was founded in 1909 and is headquartered in Barcelona, Spain.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 30, 24 | 0.15 Decreased by -9.04% | 0.21 Decreased by -28.57% |
| May 16, 24 | 0.07 Increased by +59.82% | 0.15 Decreased by -53.33% |
| Feb 29, 24 | 0.14 Increased by +118.41% | 0.22 Decreased by -36.36% |
| Nov 2, 23 | 0.11 Increased by +N/A% | 0.22 Decreased by -50.00% |
| Jul 27, 23 | 0.16 Increased by +24.92% | 0.20 Decreased by -17.18% |
| May 15, 23 | 0.04 Increased by +N/A% | 0.16 Decreased by -72.47% |
| Feb 28, 23 | 0.06 Decreased by -43.47% | 0.15 Decreased by -57.61% |
| Nov 8, 22 | 0.00 Decreased by -100.00% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 1.79 B Increased by +12.24% | 51.69 M Decreased by -13.19% | Increased by +2.88% Decreased by -22.65% |
| Jun 30, 24 | 1.82 B Increased by +9.28% | 14.84 M Decreased by -75.28% | Increased by +0.82% Decreased by -77.38% |
| Mar 31, 24 | 1.63 B Decreased by -5.08% | 21.42 M Increased by +6.72% | Increased by +1.32% Increased by +12.44% |
| Dec 31, 23 | 1.77 B Increased by +3.32% | 55.99 M Increased by +178.99% | Increased by +3.16% Increased by +170.03% |
| Sep 30, 23 | 1.60 B Increased by +3.66% | 59.54 M Increased by +33.63% | Increased by +3.73% Increased by +28.91% |
| Jun 30, 23 | 1.66 B Increased by +7.81% | 60.03 M Decreased by -33.54% | Increased by +3.61% Decreased by -38.36% |
| Mar 31, 23 | 1.71 B Increased by +42.94% | 20.07 M Increased by +151.40% | Increased by +1.17% Increased by +135.96% |
| Dec 31, 22 | 1.71 B Increased by +N/A% | 20.07 M Increased by +N/A% | Increased by +1.17% - |